Tivic Health receives NIH funding to study Entolimod for radiation protection

gr.investing.com (Greek)

Tivic Health secured NIH funding for a study of its drug Entolimod for radiation exposure. The National Institute of Allergy and Infectious Diseases will fund and conduct preclinical studies evaluating Entolimod's ability to protect gastrointestinal tissue from radiation damage. The research, starting with mice, aims to support regulatory approval for Entolimod, which has received Fast Track and Orphan Drug designations.


With a significance score of 5.1, this news ranks in the top 1.3% of today's 29680 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Tivic Health receives NIH funding to study Entolimod for radiation protection | News Minimalist